DK2734547T3 - Anvendelse af c-fms-antistoffer - Google Patents

Anvendelse af c-fms-antistoffer Download PDF

Info

Publication number
DK2734547T3
DK2734547T3 DK12735555.0T DK12735555T DK2734547T3 DK 2734547 T3 DK2734547 T3 DK 2734547T3 DK 12735555 T DK12735555 T DK 12735555T DK 2734547 T3 DK2734547 T3 DK 2734547T3
Authority
DK
Denmark
Prior art keywords
pain
leu
ser
fms
pro
Prior art date
Application number
DK12735555.0T
Other languages
English (en)
Inventor
Stefan Steidl
John Allan Hamilton
Andrew David Cook
Original Assignee
Univ Melbourne
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Melbourne, Morphosys Ag filed Critical Univ Melbourne
Application granted granted Critical
Publication of DK2734547T3 publication Critical patent/DK2734547T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Claims (7)

1. Antagonist af c-Fms til anvendelse i behandling af osteoarthritis eller smerte, hvor antagonisten er et antistof, der er specifikt for M-CSF, c-FMS eller IL-34.
2. Antagonist ifølge krav 1 til anvendelse ifølge krav 1, hvor smerten er postoperativ smerte.
3. Antagonist ifølge krav 1 til anvendelse ifølge krav 1, hvor smerten skyldes knoglecancer.
4. Antagonist ifølge krav 1 til anvendelse ifølge krav 1, hvor smerten skyldes rheumatoid arthritis.
5. Antagonist ifølge krav 1 til anvendelse ifølge krav 1, hvor smerten skyldes osteoarthritis.
6. Antagonist ifølge krav 1 til anvendelse ifølge krav 1, hvor smerten skyldes inflammation.
7. Antagonist ifølge et hvilket som helst af de foregående krav til anvendelse ifølge krav 1, hvor antagonisten anvendes til et menneske.
DK12735555.0T 2011-07-18 2012-07-17 Anvendelse af c-fms-antistoffer DK2734547T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508717P 2011-07-18 2011-07-18
EP11174305 2011-07-18
PCT/EP2012/063998 WO2013011021A1 (en) 2011-07-18 2012-07-17 Use of c-fms antagonists

Publications (1)

Publication Number Publication Date
DK2734547T3 true DK2734547T3 (da) 2017-04-03

Family

ID=47557687

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12735555.0T DK2734547T3 (da) 2011-07-18 2012-07-17 Anvendelse af c-fms-antistoffer

Country Status (8)

Country Link
US (3) US9243066B2 (da)
EP (1) EP2734547B1 (da)
JP (2) JP2014520873A (da)
AU (1) AU2012285875B2 (da)
CA (1) CA2841013C (da)
DK (1) DK2734547T3 (da)
ES (1) ES2618828T3 (da)
WO (1) WO2013011021A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2014189832A1 (en) * 2013-05-22 2014-11-27 Albert Einstein College Of Medicine Of Yeshiva University Il-34 receptor assays and uses thereof
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP6769948B2 (ja) * 2014-07-17 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−３４ポリペプチド
EP3204050A4 (en) * 2014-10-09 2018-04-04 The Regents of The University of California Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
JP6621252B2 (ja) * 2015-06-17 2019-12-18 国立大学法人北海道大学 治療耐性がんに対する治療耐性低減剤
MA44309A (fr) * 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3001969B2 (ja) 1989-02-10 2000-01-24 カイロン コーポレイション 中和配座エピトープを認識するｍ―ｃｓｆモノクローナル抗体
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP4891477B2 (ja) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． 血管新生及び／または既存細動脈網から側枝動脈及び／または他の動脈の発達の調節に関する方法
AU783063B2 (en) 1999-10-28 2005-09-22 Seyedhossein Aharinejad Use of CSF-1 inhibitors
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
PL372138A1 (en) 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
SE0200667D0 (sv) 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
US20110091451A1 (en) 2002-11-15 2011-04-21 Kavanaugh William M Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AU2003291002A1 (en) 2002-11-15 2004-06-15 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
CA2600601A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
AU2006270057A1 (en) 2005-07-18 2007-01-25 Trustees Of Boston University Method to inhibit proliferation and growth of metastases
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
US20080233118A1 (en) 2005-07-28 2008-09-25 Novartis Ag Uses Of Antibody To M-Csf
US20090181008A1 (en) 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
KR20080083187A (ko) 2006-01-05 2008-09-16 노바르티스아게 암 전이 및 암 전이와 관련된 골 소실의 예방 및 치료 방법
WO2008124129A2 (en) 2007-04-09 2008-10-16 University Of Massachusetts Treating hiv with a m-csf effector kinase inhibitor like imatinib
BRPI0815368A2 (pt) * 2007-08-21 2015-02-10 Amgen Inc "proteinas c-fms humanas a antigeno"
CN101801379A (zh) * 2007-10-18 2010-08-11 诺瓦提斯公司 治疗癌症和骨疾病的csf-1r抑制剂
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN102702358B (zh) * 2008-03-14 2016-02-17 天士力创世杰（天津）生物制药有限公司 针对csf-1r的抗体
JP2011530520A (ja) 2008-08-05 2011-12-22 ユニバーシティー オブ サウス フロリダ 認知障害を治療する方法
GB0910833D0 (en) * 2009-06-23 2009-08-05 Univ Edinburgh Avian genes
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
WO2011140249A2 (en) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
CN104271599A (zh) 2011-11-08 2015-01-07 辉瑞公司 使用抗m-csf抗体治疗炎性疾病的方法

Also Published As

Publication number Publication date
US10005840B2 (en) 2018-06-26
JP6313481B2 (ja) 2018-04-18
US20160185867A1 (en) 2016-06-30
JP2014520873A (ja) 2014-08-25
AU2012285875B2 (en) 2016-11-10
US20180237531A1 (en) 2018-08-23
EP2734547B1 (en) 2016-12-21
EP2734547A1 (en) 2014-05-28
ES2618828T3 (es) 2017-06-22
WO2013011021A1 (en) 2013-01-24
US9243066B2 (en) 2016-01-26
JP2017095484A (ja) 2017-06-01
CA2841013A1 (en) 2013-01-24
AU2012285875A8 (en) 2016-11-03
CA2841013C (en) 2020-04-21
US20140205608A1 (en) 2014-07-24
AU2012285875A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
DK2734547T3 (da) Anvendelse af c-fms-antistoffer
US9834599B2 (en) Pain treatment
DK2376121T3 (da) Slidgigtbehandling